Craniomaxillofacial Surgery Department 1 of Plastic Surgery Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
J Mol Med (Berl). 2024 Oct;102(10):1255-1266. doi: 10.1007/s00109-024-02476-y. Epub 2024 Aug 19.
Crouzon syndrome (CS), a syndromic craniosynostosis, is a craniofacial developmental deformity caused by mutations in fibroblast growth factor receptor 2 (FGFR2). Previous CS mouse models constructed using traditional gene editing techniques faced issues such as low targeting efficiency, extended lineage cycles, and inconsistent and unstable phenotypes. In this study, a CRISPR/Cas9-mediated strategy was employed to induce a functional augmentation of the Fgfr2 point mutation in mice. Various techniques, including bone staining, micro-CT, histological methods, and behavioral experiments, were employed to systematically examine and corroborate phenotypic disparities between mutant mice (Fgfr2) and their wild-type littermates. Confirmed via PCR-Sanger sequencing, we successfully induced the p.Cys361Tyr missense mutation in the Fgfr2 IIIc isoform of the extracellular domain (corresponding to the p.Cys342Tyr mutation in humans) based on Fgfr2-215 transcript (ENSMUST00000122054.8). Fgfr2 mice exhibited characteristics consistent with the phenotypic features associated with CS, including skull-vault craniosynostosis, skull deformity, shallow orbits accompanied by exophthalmos, midface hypoplasia with malocclusion, and shortened skull base, notably without any apparent limb defects. Furthermore, mutant mice displayed behavioral abnormalities encompassing deficits in learning and memory, social interaction, and motor dysfunction, without anxiety-related disorders. Histopathological examination of the hippocampal region revealed structural abnormalities, suggesting possible brain development impairment secondary to craniosynostosis. In conclusion, we constructed a novel gene-edited Fgfr2 mice strain based on CRISPR/Cas9, which displayed skull and behavioral abnormalities, serving as a new model for studying genetic molecular mechanisms and exploring treatments for CS. KEY MESSAGES: CRISPR/Cas9 crafted a Crouzon model by enhancing Fgfr2-C361Y in mice. Fgfr2 mice replicate CS phenotypes-craniosynostosis and midface anomalies. Mutant mice show diverse behavioral abnormalities, impacting learning and memory. Fgfr2 mice offer a novel model for cranial suture studies and therapeutic exploration.
克鲁宗综合征(CS)是一种综合征性颅缝早闭,是由成纤维细胞生长因子受体 2(FGFR2)基因突变引起的颅面发育畸形。以前使用传统基因编辑技术构建的 CS 小鼠模型存在靶向效率低、谱系周期长、表型不一致和不稳定等问题。在这项研究中,使用 CRISPR/Cas9 介导的策略在小鼠中诱导 FGFR2 点突变的功能增强。使用各种技术,包括骨染色、micro-CT、组织学方法和行为实验,系统地检查和证实突变小鼠(Fgfr2)与其野生型同窝仔鼠之间的表型差异。通过 PCR-Sanger 测序证实,我们成功地在 Fgfr2 的 IIIc 异构体的细胞外结构域中诱导了 p.Cys361Tyr 错义突变(对应于人类 p.Cys342Tyr 突变),基于 Fgfr2-215 转录本(ENSMUST00000122054.8)。Fgfr2 小鼠表现出与 CS 相关的表型特征一致的特征,包括颅骨穹窿颅缝早闭、颅骨畸形、眼眶浅伴眼球突出、中面部发育不良伴咬合不正以及颅底缩短,明显没有任何明显的肢体缺陷。此外,突变小鼠表现出学习和记忆、社会互动和运动功能障碍等行为异常,没有焦虑相关障碍。海马区的组织病理学检查显示结构异常,提示颅缝早闭可能导致脑发育受损。总之,我们基于 CRISPR/Cas9 构建了一种新型基因编辑 Fgfr2 小鼠品系,该品系表现出颅骨和行为异常,为研究遗传分子机制和探索 CS 治疗方法提供了一个新的模型。
CRISPR/Cas9 通过增强 Fgfr2-C361Y 在小鼠中构建了 Crouzon 模型。Fgfr2 小鼠复制 CS 表型-颅缝早闭和中面部异常。突变小鼠表现出多种行为异常,影响学习和记忆。Fgfr2 小鼠为颅缝研究和治疗探索提供了一种新的模型。